Xcout Intel
Entos Pharmaceuticals
Entos Pharmaceuticals Inc. is a clinical-stage genetic medicines company headquartered in Edmonton, Canada, specializing in the development of innovative delivery systems for genetic therapies.
Subscribe to see Entos Pharmaceuticals’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Entos Pharmaceuticals at a glance
Entos Pharmaceuticals is a biotech, pharmaceuticals company headquartered in Canada. It has raised at least $4.1M across the 2 funding rounds on record. Its most recent funding round, Grant, raised $4M in March 2025. Xcout tracks 9 named people at Entos Pharmaceuticals, including Arun Raturi (CHIEF SCIENTIFIC OFFICER).
Entos Pharmaceuticals leadership
- Arun RaturiCHIEF SCIENTIFIC OFFICER
- Kimberly HenshawCHIEF OF STAFF
- Arun RaturiFOUNDER, CHIEF EXECUTIVE OFFICER
- Duncan RoySCIENTIFIC FOUNDER
- Chandra McAllisterHEAD OF MANUFACTURING
- Jailal (Jai) AblackLEAD SCIENTIST - FORMULATIONS & PROCESS CONTROL
3 more named people on record for Entos Pharmaceuticals, with roles, board committees and tenure — see the full roster →
Entos Pharmaceuticals funding rounds
At least $4.1M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Grant | $4M | 1 named | |
| SEC Form D filing | $100,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Entos Pharmaceuticals competitors
A few of Entos Pharmaceuticals's closest competitors — see the full list of competitors and alternatives →
Damona Pharmaceuticals is a biotechnology research company developing microcircuit precision medicines aimed at restoring cognitive functions across various brain disorders. The company is located in Toronto, Ontario.
Sarepta Therapeutics, Inc. operates as a biopharmaceutical firm with products already available on the market. Its primary objective is the research and advancement of genetic treatment modalities, encompassing RNA-targeted therapeutics and gene therapies, specifically for the management of rare diseases. The company's commercial offerings include EXONDYS 51, an injectable medication prescribed for Duchenne muscular dystrophy (DMD) patients whose genetic mutation in the dystrophin gene is responsive to exon 51 skipping. Similarly, VYONDYS 53 is provided for individuals with DMD who can benefit from exon 53 skipping. Sarepta is also actively developing several investigational therapies: AMONDYS 45, a product candidate that utilizes phosphorodiamidate morpholino oligomer chemistry and exon-skipping technology to bypass exon 45 of the dystrophin gene. SRP-5051, a peptide-conjugated PMO engineered to bind to exon 51 of dystrophin pre-mRNA. SRP-9001, a gene therapy initiative focused on micro-dystrophin for DMD. SRP-9003, a gene therapy program targeting limb-girdle muscular dystrophies. The company has established collaborative relationships with various partners, including F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Sarepta was incorporated in 1980 and maintains its corporate headquarters in Cambridge, Massachusetts.
OncoSenX, Inc. is a late-stage preclinical biotechnology company headquartered in Seattle, Washington. The firm specializes in developing targeted cancer therapeutics and novel drug delivery pipelines. Its oncology technology works in coordination with parent company Entos's research platforms to advance precision gene therapies.
NanoVation Therapeutics is a platform developer headquartered in Vancouver, British Columbia, that partners with leading pharmaceutical and biotech companies to enable genetic medicines.
Encoded Therapeutics is a biotechnology company headquartered in South San Francisco, California, dedicated to developing next-generation genetic medicines designed to address the root causes of genetic diseases.
Kelonia Therapeutics, Inc. is a clinical-stage biotech company headquartered in Boston, Massachusetts, focused on delivering genetic medicine for patients.
Get Entos Pharmaceuticals's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Entos Pharmaceuticals in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access